The serum concentration of interleukin-2 in a hemodialysis patient--report from interleukin adjuvant therapy for local recurrent renal cancer

• Published in: Gan to kagaku ryoho Vol. 33; no. 3; p. 389
• Main Authors: Ishizuka, Osamu, Tanabe, Tomoaki, Nakayama, Tsuyoshi, Kinebuchi, Yoshiaki, Ogawa, Teruyuki, Nishizawa, Osamu
• Format: Journal Article
• Language: Japanese
• Published: Japan 01-03-2006
• Subjects: Adjuvants, Pharmaceutic - administration & dosage; Adult; Antineoplastic Agents - administration & dosage; Carcinoma, Renal Cell - blood; Carcinoma, Renal Cell - drug therapy; Humans; Interleukin-2 - administration & dosage; Interleukin-2 - blood; Kidney Failure, Chronic - therapy; Kidney Neoplasms - blood; Kidney Neoplasms - drug therapy; Male; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - drug therapy; Renal Dialysis
• ISSN: 0385-0684

We started interleukin-2 (IL-2) adjuvant therapy after resection of a repeated local recurrence of renal cell carcinoma in a hemodialysis patient. It is reported that IL-2 is mainly metabolized in proximal tubules of the kidney. To determine the IL-2 concentration, we employed the ELISA method using anti-human IL-2 antibodies. At the concentration of 350,000 Japan reference unit (JRU) in a hemodialysis patient, the change in serum IL-2 was almost the same speed compared to 700,000 JRU in normal renal function patients, which was reported previously. This report may also be a good tool to define the ideal dose of IL-2 in hemodialysis patients.